JP Morgan Chase
PTGX icon

JP Morgan Chase’s Protagonist Therapeutics PTGX Stock Holding History

JP Morgan Chase’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,000
Closed -$332K – 7661
2025
Q2 		$332K Buy
+6,000
New +$288K ﹤0.01% 4991
2024
Q4 		– Sell
-500
Closed -$22.5K – 7667
2024
Q3 		$22.5K Buy
+500
New +$20.2K ﹤0.01% 6214
2023
Q3 		– Sell
-218,900
Closed -$6.05M – 7673
2023
Q2 		$6.05M Buy
+218,900
New +$5.48M ﹤0.01% 2713

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase's PTGX Position: Q2 2026 in Review

JP Morgan Chase increased its Protagonist Therapeutics (PTGX) stake by 5.8% in Q2 2026, buying an estimated $1.06M and bringing the position to 183,098 shares worth $22.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2121.

JP Morgan Chase first reported a position in PTGX in Q3 2016 and has held it in 39 quarters since. The position peaked at $24.6M in Q2 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • JP Morgan Chase held 183,098 shares of Protagonist Therapeutics worth $22.6M as of Q2 2026.
  • JP Morgan Chase bought 10,108 Protagonist Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Protagonist Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2121 holding.
  • JP Morgan Chase first reported a position in Protagonist Therapeutics in Q3 2016 and has held it in 39 quarters since.
  • JP Morgan Chase's Protagonist Therapeutics position peaked at $24.6M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.